Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
life sciences
national blog main
national top stories
8
×
new york top stories
novartis
8
×
boston blog main
boston top stories
national
new york blog main
san francisco top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
clinical trials
biogen
cancer
amgen
crispr
deals
eli lilly
gene therapy
ipo
medical devices
medicare
What
new
8
×
bio
drug
roundup
fda
medicines
approval
brings
ipo
patients
remains
acquire
activity
advantages
agreed
allogene
amgen
approvals
approved
atrophy
bails
bar
billion
biogen
biogen’s
biopharmaceutical
brand
bridgebio
cancer
candidates
capital
car
cash
cholesterol
clamped
class
companies
company
compound
convo
Language
unset
Current search:
novartis
×
new
×
" national top stories "
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com
5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines